Health CanadaGeneral Alert
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, ...
Published: January 12, 2022Recall ID: 63814Category: generalCountry: Canada
Reason for Recall / Hazard
New safety information - Product safety
Product Description & Identification
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
Affected Products
XELJANZ/XELJANZ XR (tofacitinib)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63814 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/xeljanzxeljanz-xr-tofacitinib-risk-major-adverse-cardiovascular-events-malignancy |
| Issue | New safety information - Product safety |
| Title | XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection |
| Product | XELJANZ/XELJANZ XR (tofacitinib) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-01-12 |
| Organization | Marketed health products |